(Fighting New Coronary Pneumonia) The French Prime Minister said that the epidemic indicators are worrying about the Pasteur Institute's vaccine research and development
China News Agency, Paris, January 25 (Reporter Li Yang) French Prime Minister Castel said on the 25th local time that the current indicators of the new crown pneumonia epidemic in France are worrying and require people to remain vigilant.
The research and development of the new crown vaccine of the Pasteur Institute in France has been frustrated, and a major vaccine research and development project will be terminated.
Castel inspected the Health Bureau of the Greater Paris Region on the same day and listened to the epidemic report.
He affirmed the work of the Paris health system and said that medical staff are always on the frontline of the fight against the epidemic, tracking and screening the "vulnerable groups" in the epidemic, conducting epidemiological monitoring and carrying out new crown vaccination.
Castel said that all current epidemic indicators are worrying.
He asked the public to be vigilant and said that the government will make a decision on whether to conduct a third "closed city" in the near future.
The French Prime Minister's Office added that it should be cautious about the third "closure" and that "maintaining the current status quo" may also be one of the choices made by the government.
The number of new confirmed cases in a single day in France remains high, and there is a continuing upward trend.
At the same time, it is worrying that the number of hospitalized patients and the number of critically ill patients have continued to increase in recent days. The number of hospitalized patients is now close to 27,000, the highest level since December last year. At the same time, the number of critically ill patients exceeded 3,000.
The Pasteur Institute of France announced on the 25th that it will terminate a major new crown vaccine research and development project due to disappointing clinical trial results.
The Pasteur Institute stated that in the initial human clinical trials, the tested vaccine was well tolerated, but the immune response produced was not as good as that observed in patients who recovered naturally and in people who had been injected with authorized vaccines.
The scientific director of the Pasteur Institute, Dernfell, said on the same day that the termination of the vaccine research and development project does not mean the end of the research work of the Institute.
He revealed that the institute is still carrying out two vaccine research and development projects, one of which is already in the phase 1 clinical trial.
French Industry Minister Runacher said that the French pharmaceutical company Sanofi’s new crown vaccine may have to wait until next year to be on the market.
French officials hope that Sanofi’s vaccine production line can now produce vaccines that have been approved for use in EU countries, such as Pfizer vaccine and Modena vaccine.
(Finish)